

Contents

Contributors

Foreword

Preface

Acknowledgments

1. Quality Related Safety Issue—Evidence-Based Validation of Herbal Medicine Farm to Pharma

PULOK K. MUKHERJEE, SHIV BAHADUR, SUSHIL K. CHAUDHARY, AMIT KAR, KAKALI MUKHERJEE

- 1.1 Health Care through Herbal Medicine
- 1.2 Integrated Approaches for Development of Herbal Medicine
- 1.3 Use of Herbs in TM
- 1.4 Globalization of TM
- 1.5 TM Inspired Drug Discovery and Drug Development
- 1.6 Issues for Quality Control and Quality Assurance of Herbal Medicine
- 1.7 Marker Analysis and Standardization of Botanicals
- 1.8 Pharmacovigilance of Herbal Medicine
- 1.9 Safety Issues on Herbal Medicine—Cytochrome P450 Study
- 1.10 Herb-Drug Interactions
- 1.11 System Biology and Metabolomics
- 1.12 International Harmonization
- 1.13 Conclusion
- Acknowledgments
- References
- List of abbreviations

2. Value Chains of Herbal Medicines—Ethnopharmacological and Analytical Challenges in a Globalizing World

ANTHONY BOOKER, DEBORAH JOHNSTON, MICHAEL HEINRICH

- 2.1 Introduction
- 2.2 The Concept of Value Chains
- 2.3 The Medicinal Plant Value Chains—Research Needs
- 2.4 Medicinal Plant Value Chains in Asia

xi	2.5 Medicinal Plant Production in China and India	32
xiii	2.6 Supply, Demand, and Sustainability	34
xv	2.7 The Tea Value Chain	35
xvii	2.8 The Ginseng Value Chain	36
	2.9 Plant Metabolomics and Analytical Challenges	37
	2.10 Discussion	39
	Acknowledgments	42
1	References	42
	List of Abbreviations	44
2	3. Traditional Herbal Medicine, Pharmacognosy, and Pharmacopoeial Standards: A Discussion at the Crossroads	45
2	ROY UPTON R.H.	
4	3.1 Introduction	46
4	3.2 Historical Perspectives on Traditional Herbal Medicine	47
6	3.3 Modern Medicine—An American Case History	55
7	3.4 Traditional Herbal Medicines: Centuries of Empiricism	59
9	3.5 Traditional Medicine: Therapeutics, Definitions, and Orientations	61
11	3.6 Standard of Herbal Drugs in Early Pharmacopoeias	66
13	3.7 Other Qualitative Factors Not Considered in Pharmacopoeias	76
21	3.8 Preventive Care and Self-Responsibility	79
22	3.9 Conclusion	80
24	References	81
25		
28	4. Taxonomy—An Irreplaceable Tool for Validation of Herbal Medicine	87
	RAINER W. BUSSMANN	
29	4.1 Introduction	87
	4.2 Voucher Specimens	88
	4.3 Plant Identification	95
	4.4 Label Requirements for Botanical Supplements and Other Materials in Trade	97
29	4.5 The Problem of Lacking Vouchers and Incorrect Identification	97
30	4.6 Problems with the Lack of Taxonomic Attention	97
30	4.7 Conclusions	116
31	References	117

5. Validation of Medicinal Herbs for Skin Aging	
PULOK K. MUKHERJEE, SHIV BAHADUR, SUSHIL K. CHAUDHARY, RANJIT K. HARWANSH, NEELESH K. NEMA	
5.1 Introduction	119
5.2 Consequences of Herbal Cosmetic	120
5.3 Skin Aging	120
5.4 Factors Associated with Skin Aging	121
5.5 Photoprotective Mechanism of Bioactive Molecules	122
5.6 Natural Bioactive Molecules against Skin Aging	124
5.7 Few Medicinal Plants Useful in Skin Aging	128
5.8 Management of Skin Aging	128
5.9 Conclusion	141
Acknowledgments	143
References	143
List of Abbreviations	147
6. Proangiogenic Potential of Medicinal Plants in Wound Healing	
DEEPAK KASOTE, AIJAZ AHMAD, ALVARO VILJOEN	
6.1 Introduction	149
6.2 Phases of Wound Healing	150
6.3 Angiogenesis and Its Role in Wound Healing	151
6.4 Plants with Proangiogenic Potential	152
6.5 Conclusion	160
References	161
List of Abbreviations	164
7. Pharmacovigilance: Tools in Establishing the Safety and Acceptability of the Natural Health Products—Clinical Evaluation	
LUIGI GORI, FABIO FIRENZUOLI	
7.1 Introduction	165
7.2 Brief Historical Review	166
7.3 Adverse Reactions	166
7.4 Pharmacovigilance	167
7.5 Adverse Effects and Herbal Adverse Effects	167
7.6 Pharmacovigilance and Herbal Pharmacovigilance	168
7.7 Toxicologist's Toolkits	170
7.8 Conclusions	172
References	172
List of Abbreviations	174
8. Validation of Antiviral Potential of Herbal Ethnomedicine	
DEBPRASAD CHATTOPADHYAY, DURBADAL OJHA, SUPRIYA MONDAL, DEBAYAN GOSWAMI	
8.1 Introduction	175
8.2 Rationale for Antiviral Drug Development	176
8.3 Development of Effective Antiviral Drugs	177
8.4 Medicinal Plants as a Source of Antiviral Drugs: an Overview	177
8.5 Methods for the Validation of Antiviral Activity of Plants	178
8.6 Future Prospects and Directions	196
References	196
List of Abbreviations	200
9. Harmonization of Regulatory Requirements in Europe to Ensure Quality, Safety and Efficacy of Herbal Medicinal Products	
WERNER KNÖSS	
9.1 Introduction	143
9.2 HMPC: Establishment and Working Structure	143
9.3 Basic Legal Definitions and Access to the Market	147
9.4 Monographs and List Entries: Well-Established Use and Traditional Use	149
9.5 Procedure to Establish Monographs	150
9.6 Usage and Acceptance of Monographs	151
9.7 Guidance on Quality, Efficacy, and Safety: Coordination	152
9.8 Outlook	160
Conflict of Interest	161
References	164
List of Abbreviations	164
10. Bioavailability of Herbal Products: Approach Toward Improved Pharmacokinetics	
PULOK K. MUKHERJEE, RANJIT K. HARWANSH, SAUVIK BHATTACHARYYA	
10.1 Introduction	165
10.2 Factors Affecting Bioavailability and Pharmacokinetics of Herbal Products	166
10.3 The Bioavailability and Pharmacokinetics of Some Herbs and Phytoconstituents	167
10.4 Challenges in Developing a Herbal Formulation	168
10.5 Novel Drug Delivery Technology for Herbal Formulation	170
10.6 Phospholipid Complex of Herbs—Modification of Bioavailability and Efficacy	172
10.7 Conclusion	172
Acknowledgment	174
References	176
List of Abbreviations	176
11. Antiviral Potential of Medicinal Plants	
DEBPRASAD CHATTOPADHYAY, DURBADAL OJHA, SUPRIYA MONDAL, DEBAYAN GOSWAMI	
11.1 Introduction	177
11.2 Rationale for Antiviral Drug Development	177
11.3 Development of Effective Antiviral Drugs	178
11.4 Medicinal Plants as a Source of Antiviral Drugs: an Overview	178
11.5 Methods for the Validation of Antiviral Activity of Plants	179
11.6 Future Prospects and Directions	196
References	196
List of Abbreviations	200
12. Harmonization of Regulatory Requirements in Europe to Ensure Quality, Safety and Efficacy of Herbal Medicinal Products	
WERNER KNÖSS	
12.1 Introduction	143
12.2 HMPC: Establishment and Working Structure	143
12.3 Basic Legal Definitions and Access to the Market	147
12.4 Monographs and List Entries: Well-Established Use and Traditional Use	149
12.5 Procedure to Establish Monographs	150
12.6 Usage and Acceptance of Monographs	151
12.7 Guidance on Quality, Efficacy, and Safety: Coordination	152
12.8 Outlook	160
Conflict of Interest	161
References	164
List of Abbreviations	164
13. Bioavailability of Herbal Products: Approach Toward Improved Pharmacokinetics	
PULOK K. MUKHERJEE, RANJIT K. HARWANSH, SAUVIK BHATTACHARYYA	
13.1 Introduction	165
13.2 Factors Affecting Bioavailability and Pharmacokinetics of Herbal Products	166
13.3 The Bioavailability and Pharmacokinetics of Some Herbs and Phytoconstituents	167
13.4 Challenges in Developing a Herbal Formulation	168
13.5 Novel Drug Delivery Technology for Herbal Formulation	170
13.6 Phospholipid Complex of Herbs—Modification of Bioavailability and Efficacy	172
13.7 Conclusion	172
Acknowledgment	174
References	176
List of Abbreviations	176

11. Good Quality and Clinical Practices for the Future Development of Herbal Medicines	247	14. Drugs and Drug Leads Based on Natural Products for Treatment and Prophylaxis of Malaria	307
GAIL B. MAHADY		SØREN BRØGGER CHRISTENSEN	
11.1 Introduction	247	14.1 Malaria	307
11.2 Quality Issues: Lack of GMP or Failure to Comply with cGMP Guidelines	249	14.2 Drug for Treatment of Malaria	309
11.3 Safety of HMs in the United States, Europe, and Asia	250	14.3 Malaria Prevention through Vector Control	314
11.4 Efficacy: The Importance of Randomized Controlled Clinical Trials	253	14.4 Evidence-based Use of Phytomedicines	314
11.5 Future Outlook for HMs	255	14.5 Conclusion	317
References	256	References	318
List of Abbreviations	258	15. Evaluation of Natural Products against Biofilm-Mediated Bacterial Resistance	321
		TUHINADRI SEN, SANMOY KARMAKAR, RATUL SARKAR	
12. Traditional Medicine-Inspired Evidence-Based Approaches to Drug Discovery	259	15.1 Introduction	321
BHUSHAN PATWARDHAN		15.2 Biofilm Formation	323
12.1 Introduction	259	15.3 Mechanism for Resistance due to Biofilm	324
12.2 Ayurveda Inspiration	260	15.4 Biofilm and Quorum Sensing	325
12.3 Reverse Pharmacology	262	15.5 Quorum Sensing as a Target for Antimicrobial Therapy	329
12.4 <i>Semecarpus anacardium</i> Case	262	15.6 Natural Products as a QS Inhibitor	331
12.5 Formulation Discovery	263	15.7 Synergy with the Natural Products and Conventional Antibiotics	332
12.6 Phytopharmaceuticals as Drugs	264	15.8 Conclusions	332
12.7 Clinical Research	264	Acknowledgments	334
12.8 The Artrex Story	265	References	334
12.9 Formulations for Arthritis	265	List of Abbreviations	338
12.10 Rasayana and Immunoadjuvants	266	16. Clinical Effects of Caraway, a Traditional Medicine for Weight Loss	339
12.11 Discovery Approaches	268	MAHNAZ KAZEMIPOOR, GEOFFREY A. CORDELL	
12.12 Herb–Drug Interactions	268	16.1 Introduction	339
12.13 Quality Control and Standardization	268	16.2 Materials and Methods	347
12.14 Evidence-Based Ayurvedic Medicine	269	16.3 Results	348
12.15 Conclusion	269	16.4 Discussion	352
References	269	16.5 Conclusions	357
		16.6 Summary	357
13. Evaluation of Bioactive Compounds as Acetylcholinesterase Inhibitors from Medicinal Plants	273	Acknowledgment	357
SANTANU BHADRA, MANOJ K. DALAI, JOYDEB CHANDA, PULOK K. MUKHERJEE		References	357
13.1 Introduction	274	List of Abbreviations	362
13.2 Cholinergic Pathway	274	17. Challenges in Identification of Potential Phytotherapies from Contemporary Biomedical Literature	363
13.3 Cholinesterase Inhibitors for Learning and Memory	275	INDRA NEIL SARKAR	
13.4 Medicinal Plants for the Management of Cognitive Disorder	277	17.1 Description of Medicinal Uses of Plants	363
13.5 Phytoconstituents for the Management of Cognitive Disorder	283	17.2 Biomedical Literature	364
13.6 Conclusion	302	17.3 Concept Recognition	365
Acknowledgments	302	17.4 Identifying Potential Plant–Therapy Relationships	368
References	302	17.5 Conclusion	369
List of Abbreviations	306	References	369
		List of Abbreviations	371

18. Botanicals as Medicinal Food and Their Effects against Obesity	373	21. Discovery and Development of Lead Compounds from Natural Sources Using Computational Approaches	455
KAKALI MUKHERJEE, RAJARSHI BISWAS, SUSHIL K. CHAUDHARY, PULOK K. MUKHERJEE		JOSÉ L. MEDINA-FRANCO	
18.1 Introduction	373	21.1 Introduction	455
18.2 Pathogenesis of Obesity and Management Strategies	374	21.2 NPs in Drug Discovery	457
18.3 Phytochemicals Useful against Metabolic Disorder	377	21.3 Chemoinformatic Analysis of Natural Products	457
18.4 Herb as Food Useful in Obesity Management	387	21.4 Molecular Databases Focused on NPs and NP Derivatives	462
18.5 Medicinal Plant for Treatment of Obesity	396	21.5 Virtual Screening and Target Fishing	464
18.6 Prospect of Phytochemicals, Foods and Botanicals in Obesity Management	397	21.6 NPs as Leads for Challenging and Emerging Targets	466
18.7 Conclusion	398	21.7 Uncovering Bioactivities of NPs of Dietary Origin	469
Acknowledgment	398	21.8 Concluding Remarks	470
References	398	Acknowledgments	470
List of Abbreviations	402	References	470
		List of Abbreviations	475
19. Applications of High Performance Liquid Chromatography in the Analysis of Herbal Products	405	22. Infrared Spectroscopic Technologies for the Quality Control of Herbal Medicines	477
SATYAJIT D. SARKER, LUTFUN NAHAR		CHRISTIAN HUCK	
19.1 Introduction	406	22.1 Introduction	477
19.2 High Performance Liquid Chromatography (HPLC)	406	22.2 Technical Principles	478
19.3 Herbal Products	410	22.3 IR Imaging Spectroscopy	480
19.4 Types of Analysis of Herbal Products	411	22.4 Chemometrics Including Data Preprocessing	483
19.5 Analysis of Herbal Products by High Performance Liquid Chromatography	414	22.5 Ad- and Disadvantages of NIR and Imaging Spectroscopy	484
19.6 Conclusions	423	22.6 Quantitative Analysis of Secondary Metabolites	484
References	423	22.7 Qualitative Analysis: Classification, Discrimination and/or Authentication	489
List of Abbreviations	425	22.8 IR Imaging Spectroscopy Studies	490
		22.9 Regulatory Issues	491
20. Ayurveda – Opportunities for Developing Safe and Effective Treatment Choices for the Future	427	Acknowledgments	491
PRATIP K. DEBNATH, SUBHADIP BANERJEE, PARIKSHIT DEBNATH, ACHINTYA MITRA, PULOK K. MUKHERJEE		References	491
20.1 Ayurveda the Science of Life	428	List of Abbreviations	493
20.2 Knowledge Base of Ancient India	432		
20.3 <i>Dravyaguna</i> : Pharmacodynamic Classification of Herbs in Ayurveda	434	23. Antimicrobial Secondary Metabolites—Extraction, Isolation, Identification, and Bioassay	495
20.4 <i>Nidana Samprapti</i> : Disease Pathogenesis in Ayurveda	435	MUKHLESUR RAHMAN	
20.5 <i>Panchakarma Therapy</i> : Personalized Detoxification and Rejuvenation Therapy	438	23.1 Introduction	495
20.6 Ayurveda: Rediscovering Novel Therapies	442	23.2 Extraction and Isolation of Metabolites for Antimicrobial Potentials	497
20.7 <i>Rasashastra</i> : The Mystery of Ancient Chemistry	446	23.3 Identification of Compounds	498
20.8 Ayur-Pharmacoepidemiology	448	23.4 Bioassay: Methods Commonly Used for the Screening of Antimicrobial Activity	500
20.9 Conclusion	450	23.5 Antimicrobial Secondary Metabolites	502
References	451	23.6 Conclusion	509
		References	510
		List of Abbreviations	512

24. Uses of Herbals in Cardiac Diseases: Priority of Evidence Over Belief	515	24.6 Medicinal Plants Used for Cardiovascular Diseases Other than Indian Medicinal Plants	520
SUBIR K. MAULIK, SANJAY K. BANERJEE		24.7 Data Obtained from Human Studies with Medicinal Plants for Cardiovascular Effects	520
24.1 Introduction	515	24.8 Indian Initiatives	526
24.2 Epidemiology of CVD	516	24.9 Conclusion	526
24.3 Herbal Drug versus Modern Medicine	516	References	526
24.4 Validation of Indian Medicinal Plants for Cardioprotection	516	List of Abbreviations	529
24.5 Experimental Data Obtained from Indian Medicinal Plants for Cardiovascular Activity	517	Index	531